Cancer Cell Research (Online ISSN: 2161-2609)

Cancer Cell Research 2020 7(28) 749-754; published online  15 December 2020

Abstract: To explore and observe the effect of DC-CIK maintenance therapy combined with traditional Chinese medicine treatment on the improvement of quality of life in patients with advanced non-small cell lung cancer (NSCLC). The research period was from January 2017 to April 2018. 89 patients with advanced NSCLC who were diagnosed and treated in our hospital. They were divided into observation group 49 cases and control group 40 cases. Record the improvement of the quality of life. After treatment, the short-term total effective rates of the observation group and the control group were 71.4% and 42.5% respectivel. The rate of the observation group was significantly higher than that of the control group (P<0.05). CD8+, CD3+ and CD4+ in the observation group and the control group after treatment were significantly different from those before treatment. And there was a statistically significant difference (P<0.05). DC-CIK maintenance therapy combined with traditional Chinese medicine treatment of advanced NSCLC patients can improve the quality of life, improve the body's immune ability, reduce the occurrence of adverse reactions, thereby improving the therapeutic effect.

Cancer Cell Research 2020 7(28) 755-758; published online   29 November 2020

Abstract: To explore the effect of citalopram combined with psychological intervention on cellular immune function and negative emotion in patients with primary liver cancer. 124 patients with primary liver cancer from June 2018 to August 2019 were selected. 62 in the observation and 62 in the control. In the control received routine interventional therapy for liver cancer, while in the observation were treated with ciplatan combined with psychological intervention. Before and after treatment, CD3 +, CD4 +, CD4 + / CD8 +, NK cells and other cellular immune indexes were compared; core quality of life scale scores of cancer patients before and after treatment were compared; MMSE, HAMD and HAMA scores. Results: The levels of CD3 +, CD4 +, CD4 + / CD8 + and NK cells in the observation were higher than in the control after treatment. After treatment, MMSE 83.17 ± 4.47, HAMD 67.51 ± 7.71 and HAMA 60.42 ± 5.83 in the observation group were higher than those in the control group. Citalopram combined with psychological intervention in the treatment of patients with primary liver cancer is conducive to the protection of cellular immune function, and has positive significance in regulating patients' mood, improving patients' psychology and improving patients' quality of life.

Cancer Cell Research 2020 7(28) 759-772; published online   22 November 2020

Abstract: Colon cancer is the second leading cause of cancer-related mortalities worldwide and the third in the United States. Current colon cancer treatments, including surgery, chemotherapy, and radiotherapy, have adverse effects and significantly decrease patients’ quality of life. Developing treatments without side effects is critical in helping American colon cancer patients have a healthy life. Phytochemicals are nonnutritious compounds present in plants, exert various health benefits with low side effects, particularly cancer. However, the required dosages to exert anti-colon cancer effects of the phytochemicals are too high to be achieved by dietary intake. Increasing evidence supports that combining two or more phytochemicals synergistically inhibits cancer cell proliferation and tumor growth in cells and animals. This mini-review focused on two phytochemical curcumin and luteolin, combined or the individual on the anti-colon cancer effects and mechanisms in cells, animals, and humans. We conclude that combining phytochemicals may be a practical approach to treat colon cancer in humans after more extensive investigations.

Cancer Cell Research 2020 7(28) 773-777; published online   29 November 2020

Abstract: To investigate the relationship between ER status, P53, WT1, CA125 and clinical characteristics of epithelial ovarian cancer, and the differential diagnosis value of low grade and high grade serous ovarian cancer. 34 patients with epithelial ovarian cancer admitted to our hospital were selected as the research object, and divided into low grade group and high grade group according to the histological grade of ovarian cancer. The immunohistochemical expressions of ER, P53 and WT1 in the two groups were compared and analyzed, and their correlation and clinicopathological parameters were analyzed. The total positive rates of P53 and WT1 in ovarian cancer were 55.88% and 41.18%. The proportion of P53 positive expression in high-grade group was significantly higher than that in low-grade group, while the WT1 positive rate was lower than that in low-grade group, the difference was statistically significant (P < 0.05). The WT1 (+) &P53 (+) group had a higher level of CA125 than the non-expression group, and the difference was statistically significant (P < 0.05). WT1 protein was significantly correlated with pathological stage, degree of differentiation, pathological type and lymph node metastasis of epithelial ovarian cancer (P < 0.05), which could be used as an important prognostic factor for patients.The expression level of P53 is higher in high-grade serous ovarian cancer, while the expression level of WT1 is lower. The use of P53 and WT1 can diagnose high-grade serous ovarian cancer, and WT1 has higher diagnostic value for low-grade serous ovarian cancer. The CA125 status was significantly correlated with the expression of P53 and WT1.

Cancer Cell Research 2020 7(28) 778-785; published online   29 November 2020

Abstract: KRAS is a member of the human RAS gene family and is one of the first oncogenes discovered. KRAS mutation is a key driving factor of non-small cell lung cancer (NSCLC). In NSCLC, the mutation rate of this driver gene reaches 20-25%, which can mediate the signal transduction between downstream pathway. The membrane growth factor is closely related to tumorigenesis and development, such as the RAS / RAF / MEK / ERK pathway and the PI3K / AKT / mTOR pathway. Therefore, for NSCLC with KRAS mutations, targeting KRAS has great clinical therapeutic value. Researchers have always been committed to finding drugs that can inhibit KRAS itself or key molecules in the KRAS signaling pathway. The related clinical trials have ended in failure. Therefore, in patients with NSCLC, treatment for KRAS mutations is urgently needed. This paper reviews the research progress of RAS gene and KRAS mutation in NSCLC therapy.